Literature DB >> 9247667

Serum S-100 protein, relationship to clinical outcome in acute stroke.

H D Abraha1, R J Butterworth, P M Bath, W S Wassif, J Garthwaite, R A Sherwood.   

Abstract

The clinical significance of serum S-100 protein, a protein released by damaged brain tissue, was assessed in patients with acute ischaemic or haemorrhagic stroke and matched controls. Serum S-100 protein concentration was significantly elevated in patients with ischaemic stroke [median (SQR): 0.27 (0.90) microgram/L, n = 68] and haemorrhagic stroke [0.43 (0.23 microgram/L, n = 13] compared to controls [0.11 (0.03) microgram/L, n = 51, P < 0.0001]. Although patients with haemorrhagic stroke had higher serum S-100 concentrations compared to patients with ischaemic stroke, this was not quite statistically significant. Serum S-100 concentrations were related to infarct size, large (total anterior circulation) infarcts concentrations having the highest [0.40 (0.22) microgram/L], and small vessel ('lacunar') infarcts concentrations having the lowest [0.20 (0.60) microgram/L, P < 0.0005] concentrations. S-100 protein concentration was also significantly related to clinical outcome at three months measured using three disability and handicap scales (n = 81): modified Barthel index (rs = -0.285, P = 0.01), modified Rankin score (rs = 0.313, P = 0.004) and Lindley score (rs = 0.262, P = 0.018) with high values associated with poor clinical outcome. Similarly high values of serum S-100 protein were observed in patients who died or were discharged to an institution [median (SQR): 0.63 (0.29) microgram/L and 0.37 (0.13) microgram/L, respectively compared to those who were discharged home [0.26 (0.11) microgram/L, P = 0.13]. The present study suggests measurement of serum S-100 protein could be a useful prognostic marker of clinical outcome in acute stroke. Whether S-100 concentrations can be altered by therapeutic intervention in acute stroke remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247667     DOI: 10.1177/000456329703400405

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  15 in total

Review 1.  [Neuromonitoring with S-100 protein in the intensive care unit].

Authors:  M Fries; J Bickenbach; S Beckers; D Henzler; R Rossaint; R Kuhlen
Journal:  Anaesthesist       Date:  2004-10       Impact factor: 1.041

2.  Diagnostic value of Elecsys S100 as a marker of acute brain injury in the emergency department.

Authors:  Eun-Jee Oh; Young-Min Kim; Dong-Wook Jegal; Jimin Kahng; Yeon-Joon Park; Kyungja Han
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

3.  Assessment of neuron-specific enolase, S100B and malondialdehyde levels in serum and vitreous of patients with proliferative diabetic retinopathy.

Authors:  Vusala Asadova; Zulfiye Gul; Rifat Levent Buyukuysal; Ozgur Yalcinbayir
Journal:  Int Ophthalmol       Date:  2019-09-30       Impact factor: 2.031

4.  Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke.

Authors:  Michael T Wunderlich; Thorsten Hanhoff; Michael Goertler; Friedrich Spener; Jane F C Glatz; Claus-W Wallesch; Maurice M A L Pelsers
Journal:  J Neurol       Date:  2005-04-18       Impact factor: 4.849

5.  Serum S100beta protein as a marker of disease activity in patients with malignant melanoma.

Authors:  M Q Mohammed; H D Abraha; R A Sherwood; K MacRae; S Retsas
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

Review 6.  Sensitization and tolerization to brain antigens in stroke.

Authors:  K J Becker
Journal:  Neuroscience       Date:  2008-07-25       Impact factor: 3.590

Review 7.  S100 as a marker of acute brain ischemia: a systematic review.

Authors:  David L Nash; M Fernanda Bellolio; Latha G Stead
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

8.  S100B and brain natriuretic peptide predict functional neurological outcome after intracerebral haemorrhage.

Authors:  Michael L James; Robert Blessing; Barbara G Phillips-Bute; Ellen Bennett; Daniel T Laskowitz
Journal:  Biomarkers       Date:  2009-09       Impact factor: 2.658

9.  Induction of immunologic tolerance to myelin basic protein prevents central nervous system autoimmunity and improves outcome after stroke.

Authors:  J Michael Gee; Angela Kalil; Matthew Thullbery; Kyra J Becker
Journal:  Stroke       Date:  2008-03-06       Impact factor: 7.914

10.  Determining the Feasibility of Ambulance-Based Randomised Controlled Trials in Patients with Ultra-Acute Stroke: Study Protocol for the "Rapid Intervention with GTN in Hypertensive Stroke Trial" (RIGHT, ISRCTN66434824).

Authors:  Sandeep Ankolekar; Gillian Sare; Chamila Geeganage; Michael Fuller; Lynn Stokes; Nikola Sprigg; Ruth Parry; A Niroshan Siriwardena; Philip M W Bath
Journal:  Stroke Res Treat       Date:  2012-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.